ctDNA是肿瘤患者外周血中存在的无细胞状态的胞外DNA,可动态评估肿瘤情况,并能克服肿瘤的异质性偏倚。2023年美国癌症研究协会(AACR)年会于2023年4月14日至19日在美国奥兰多举行,在本次AACR大会中,有三项ctDNA相关研究评估了其在泌尿肿瘤中的应用价值。 #1 循环肿瘤DNA和转录组分析在预测肌层浸润性膀胱癌患者预后中...
5. 安罗替尼联合PARP抑制剂作为靶向MSLN和CD19的TGFβ不敏感的CAR-T细胞治疗在晚期卵巢癌的桥接治疗 3997/6 - PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer 通讯作者:华中科技大学同济医学院附属同济医院 高庆...
CT192/20 - A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies 主要研究者:巴一 内容概要:TQB2916注射液I期临床研究采用贝叶斯最优区间(BOIN)设计,评估最大耐受剂量(MTD)和2期...
2023年8月3日,益方生物发公告与正大天晴就KRAS G12C抑制剂D-1553(Garsorasib)签署《许可与合作协...
(100 mCi, 3700 kBq), induced complete tumor regression and long-term survival of > 50% of mice harboring established syngeneic radioresistant colorectal CT26 tumors expressing human 4Ig-B7-H3 compared to vector control tumors (* p = 0.0376, log-rank test) 90Y-DOTA-MIL33B-responsive mice ...
Therapex said it has presented the preclinical trial results of TRX-221, its fourth-generation non-small cell lung cancer (NSCLC) drug candidate, at the American Association for Cancer Research (AACR) 2023 Conference in Orlando, Florida, the U.S., on Tuesday. ...
Lunit said it will present five poster presentations featuring its AI-biomarker platform, Lunit SCOPE IO, during the 2023 American Association for Cancer Research (AACR) annual meeting in Orlando, Florida, from April 14-19.One of the studies to be presen
被誉为全球癌症研究风向标的美国癌症研究协会年会AACR,近日发布了2021年度参展的全球肿瘤领域最前沿的研究成果。早在前几天,Arvinas公司便发布消息,即将公布两款PROTAC的结构。至此,万众瞩目的PROTAC分子ARV110、ARV471结构已曝光,快来一睹风采。 ARV-...
摘要标题:A first-in-human phase I study of TQB2916, a novel CD40 agonist antibody for advanced malignancies 内容摘要:本临床研究采用贝叶斯最优区间(BOIN)设计,评估最大耐受剂量(MTD)和II期临床研究推荐剂量(RP2D)。 研究结果:2022年4月到2023年11月,研究共入组18例实体瘤和2例淋巴瘤受试者,接受 TQB...
摘要标题:A first-in-human phase I study of TQB2916, a novel CD40 agonist antibody for advanced malignancies 内容摘要:本临床研究采用贝叶斯最优区间(BOIN)设计,评估最大耐受剂量(MTD)和II期临床研究推荐剂量(RP2D)。 研究结果:2022年4月到2023年11月,研究共入组18例实体瘤和2例淋巴瘤受试者,接受 TQB...